ATE373656T1 - Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel - Google Patents

Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel

Info

Publication number
ATE373656T1
ATE373656T1 AT01943522T AT01943522T ATE373656T1 AT E373656 T1 ATE373656 T1 AT E373656T1 AT 01943522 T AT01943522 T AT 01943522T AT 01943522 T AT01943522 T AT 01943522T AT E373656 T1 ATE373656 T1 AT E373656T1
Authority
AT
Austria
Prior art keywords
hydrogen
group selected
production
alkylsulphonylaminocarbonyl
optionally substituted
Prior art date
Application number
AT01943522T
Other languages
English (en)
Inventor
Antonio Longo
Maria Brasca
Paolo Orsini
Gabriella Traquandi
Valeria Pittala
Anna Vulpetti
Mario Varasi
Paolo Pevarello
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE373656T1 publication Critical patent/ATE373656T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01943522T 2000-06-19 2001-06-13 Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel ATE373656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/597,274 US6335342B1 (en) 2000-06-19 2000-06-19 Azaindole derivatives, process for their preparation, and their use as antitumor agents

Publications (1)

Publication Number Publication Date
ATE373656T1 true ATE373656T1 (de) 2007-10-15

Family

ID=24390825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943522T ATE373656T1 (de) 2000-06-19 2001-06-13 Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel

Country Status (11)

Country Link
US (2) US6335342B1 (de)
EP (1) EP1309590B1 (de)
JP (1) JP2004501152A (de)
KR (1) KR20030010739A (de)
AT (1) ATE373656T1 (de)
AU (2) AU6607901A (de)
CA (1) CA2411865A1 (de)
DE (1) DE60130562D1 (de)
MX (1) MXPA02012166A (de)
NZ (1) NZ523002A (de)
WO (1) WO2001098299A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101027302B (zh) * 2004-07-27 2011-05-11 Sgx药物公司 吡咯并吡啶激酶调节剂
MX2007001127A (es) * 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Moduladores de pirrolo-piridina cinasa.
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006040049A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Novel azaindole thiazolinones as anti-cancer agents
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
FR2884821B1 (fr) * 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
EP1881983B1 (de) * 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridine als proteinkinasehemmer
FR2887881B1 (fr) * 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
US20070149506A1 (en) * 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUE030235T2 (en) 2005-12-13 2017-04-28 Incyte Holdings Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
JP5244118B2 (ja) * 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
JP5337717B2 (ja) 2007-02-27 2013-11-06 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なイソキノリノピロロピリジノン
EP1980561B1 (de) 2007-03-30 2013-10-09 Nerviano Medical Sciences S.R.L. Substituierte 1h-Pyrazolo[3,4-b]-pyridin-Derivate, die als Kinasehemmer aktiv sind
EP2002836B1 (de) 2007-05-31 2010-10-20 Nerviano Medical Sciences S.r.l. Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken
EP2003129B1 (de) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP3070090B1 (de) 2007-06-13 2018-12-12 Incyte Holdings Corporation Verwendung der salze des janus-kinasehemmers (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
BRPI0817860A2 (pt) * 2007-10-22 2019-09-24 Orchid Res Laboratories Limited inibidores de histona deacetilase
EP2070928A1 (de) * 2007-12-12 2009-06-17 NERVIANO MEDICAL SCIENCES S.r.l. Als Kinasehemmer wirkende 7-Azaindol-3-ylacrylamide
CL2009000447A1 (es) * 2008-02-29 2010-01-04 Array Biopharma Inc Y Genentech Inc Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EA020494B1 (ru) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2266562A1 (de) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Verwendung von Indol-Derivaten zur Krebsbehandlung
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
BR112012020693B1 (pt) * 2010-02-18 2020-05-12 Incyte Holdings Corporation Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
DK2558446T5 (da) 2010-04-16 2019-12-09 Ac Immune Sa Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner
EP3087972A1 (de) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topische formulierung für einen jak-hemmer
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
EP2640725B1 (de) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclensubstituierte pyrrolopyridine und pyrrolopyrimidine als jak-inhibitoren
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
KR102024948B1 (ko) 2011-02-18 2019-11-04 노파르티스 파르마 아게 mTOR/JAK 저해제 병용 요법
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
KR101964479B1 (ko) * 2011-03-31 2019-04-01 카나 바이오사이언스, 인코포레이션 신규 푸라논 유도체
JP2014516084A (ja) * 2011-06-10 2014-07-07 グラクソスミスクライン、インテレクチュアル、プロパティー、リミテッド 新規化合物
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR20220162825A (ko) 2012-11-15 2022-12-08 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
PL2928864T3 (pl) * 2012-12-07 2020-06-15 Biokinesis Nowe pochodne indolu do leczenia nowotworu, zakażeń wirusowych i chorób płuc
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
CN104119331B (zh) * 2013-04-26 2018-02-06 广东东阳光药业有限公司 烯基化合物及其使用方法和用途
WO2014193647A2 (en) * 2013-05-26 2014-12-04 Calitor Sciences, Llc Alkenyl compounds and methods of use
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
JP2017503815A (ja) * 2014-01-24 2017-02-02 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド がんまたは炎症性疾患を処置するための置換されたピロロピリジンおよびピロロピラジン
EP3100742B1 (de) 2014-01-31 2020-05-20 Carna Biosciences Inc. Zusammensetzung für antikrebsmittel mit einem cdc7-hemmer und einem wee1-hemmer
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
MX2017009571A (es) 2015-01-23 2018-09-27 Aclaris Therapeutics Inc Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EP3307724B1 (de) * 2015-06-12 2020-06-10 National University of Singapore (z)-2-(1h-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitril-derivate und ähnliche verbindungen mit lysosomhemmender und anti-mitotischer wirkung zur behandlung von hyperproliferativen erkrankungen
US10287401B2 (en) 2015-07-01 2019-05-14 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
EP3529243B1 (de) 2016-10-24 2024-02-28 Evexta Bio (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitril zur behandlung von endometriose
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
TWI797242B (zh) 2018-01-30 2023-04-01 美商英塞特公司 製備ｊａｋ抑制劑之方法及中間物
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5952355A (en) * 1993-11-17 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
US5977131A (en) * 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
KR20030010739A (ko) 2003-02-05
DE60130562D1 (de) 2007-10-31
EP1309590B1 (de) 2007-09-19
US6335342B1 (en) 2002-01-01
US6486322B1 (en) 2002-11-26
JP2004501152A (ja) 2004-01-15
AU2001266079B2 (en) 2006-08-24
WO2001098299A1 (en) 2001-12-27
CA2411865A1 (en) 2001-12-27
EP1309590A1 (de) 2003-05-14
US20030004350A1 (en) 2003-01-02
NZ523002A (en) 2004-09-24
MXPA02012166A (es) 2003-04-25
AU6607901A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
ATE373656T1 (de) Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
CY1117132T1 (el) Παραγωγο θειαζολιου
DE60000611T2 (de) 4-oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamide als antivirale mittel
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
ATE208779T1 (de) Substituierte spiroheterocyclische 1h-3-aryl- pyrrolidin-2,4-dion-derivate, verfahren zu deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
YU55603A (sh) Derivati purina kao antagonisti purinergiskog receptora
BG102316A (en) Derivatives of quinolin-2(1h)-on, serotonin antagonists
CA2244139A1 (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
MY131762A (en) Pharmaceutical compounds
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
ATE223925T1 (de) 2,2'-disubstituierte 1,1'-diphosphino-ferrocene und 1',2-disubstituierte 1-phosphino-ferrocene, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende übergangsmetallkomplexe
ATE194611T1 (de) Optisch aktive imidazolidinon-derivate und verfahren zu deren herstellung
ATE269329T1 (de) Neue basische derivate von benz(e)isoindol-1-onen und pyrrolo(3,4-c)chinolin-1-onen mit 5-ht3- antagonistischer aktivität, ihre herstellung und ihre therapeutische verwendung
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
EP0884318A4 (de) Kondensierte purinderivate
ES2111086T3 (es) Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos.
DE3776443D1 (de) Pyrimidinderivate und verfahren zu ihrer herstellung.
NZ291855A (en) Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists
ES2128960A1 (es) Derivados de fluorofenil-triazinas y pirimidinas compuestos farmacologicamente activos en el sistema nervioso central.
HUP0104045A2 (hu) Eljárás 4-[(2',5'-diamino-6'-halogén-pirimidin-4'-il)-amino]-ciklopent-2-enilmetanol-származékok előállítására
BG108423A (en) Dihydroimidazo[5,1-a]beta-carboline derivatives, method for preparing same and use thereof as medicine
MY138045A (en) New benzo[b]pyrano[3,2-h]acridin-7-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them
EP1724270A3 (de) Phenylacetamido-thiazole Verbindungen, Verfahren zu ihren Herstellung und ihre Anwendung als antitumor Mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties